$Table 2 from Phase II Clinical Trial and Preclinical Evaluation of a Novel CD47 Blockade Combination in Refractory Microsatellite-Stable Metastatic Colorectal Cancer$

Table 2 from Phase II Clinical Trial and Preclinical Evaluation of a Novel CD47 Blockade Combination in Refractory Microsatellite-Stable Metastatic Colorectal Cancer

<p>Treatment-emergent adverse events by Common Terminology Criteria for Adverse Events v5.0, grade 1–4 occurring in at least 10% of patients and all grade 5, at the patient level.</p>

Enregistré dans:

Détails bibliographiques
Auteur principal:	Robert W. Lentz (17013559) (author)
Autres auteurs:	Julie Lang (20519739) (author), Todd M. Pitts (17013577) (author), Patrick Blatchford (22652193) (author), Junxiao Hu (16157686) (author), Kimberly R. Jordan (15049505) (author), Adrie Van Bokhoven (22652196) (author), Stacey M. Bagby (17013565) (author), Adrian T.A. Dominguez (19529151) (author), Cameron A. Binns (22652199) (author), Hannah R. Robinson (19529136) (author), Nicole Balmaceda (22652202) (author), Emily Baiyee (22652205) (author), Alexis D. Leal (17013562) (author), Sunnie S. Kim (19529139) (author), S. Lindsey Davis (14032353) (author), Christopher H. Lieu (15018279) (author), Raymond C. Wadlow (22652208) (author), Kristen Spencer (22652211) (author), Aaron J. Scott (15133937) (author), Patrick M. Boland (15037142) (author), Howard S. Hochster (15022088) (author), Wells A. Messersmith (17013568) (author)
Publié:	2025
Sujets:	Cancer Immuno-oncology Clinical Research and Trials Clinical Trial Results Phase II clinical trials Checkpoint Blockade Colorectal Cancer Combination Immunotherapy Gastrointestinal Cancers Immunotherapy
Tags:	Ajouter un tag Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires

Figure 1 from Phase II Clinical Trial and Preclinical Evaluation of a Novel CD47 Blockade Combination in Refractory Microsatellite-Stable Metastatic Colorectal Cancer
par: Robert W. Lentz (17013559)
Publié: (2025)

Figure 2 from Phase II Clinical Trial and Preclinical Evaluation of a Novel CD47 Blockade Combination in Refractory Microsatellite-Stable Metastatic Colorectal Cancer
par: Robert W. Lentz (17013559)
Publié: (2025)

Figure 3 from Phase II Clinical Trial and Preclinical Evaluation of a Novel CD47 Blockade Combination in Refractory Microsatellite-Stable Metastatic Colorectal Cancer
par: Robert W. Lentz (17013559)
Publié: (2025)

Figure 4 from Phase II Clinical Trial and Preclinical Evaluation of a Novel CD47 Blockade Combination in Refractory Microsatellite-Stable Metastatic Colorectal Cancer
par: Robert W. Lentz (17013559)
Publié: (2025)

Table 1 from Phase II Clinical Trial and Preclinical Evaluation of a Novel CD47 Blockade Combination in Refractory Microsatellite-Stable Metastatic Colorectal Cancer
par: Robert W. Lentz (17013559)
Publié: (2025)

Supplementary Table 1 from Phase II Clinical Trial and Preclinical Evaluation of a Novel CD47 Blockade Combination in Refractory Microsatellite-Stable Metastatic Colorectal Cancer
par: Robert W. Lentz (17013559)
Publié: (2025)

Supplementary Table 3 from Phase II Clinical Trial and Preclinical Evaluation of a Novel CD47 Blockade Combination in Refractory Microsatellite-Stable Metastatic Colorectal Cancer
par: Robert W. Lentz (17013559)
Publié: (2025)

Supplementary Table S1 from Checkpoint Blockade Combinations in Tumor Mutational Burden/Load-High Tumors: Insights from the Atezolizumab + Bevacizumab and Nivolumab + Ipilimumab Cohorts in the Drug Rediscovery Protocol
par: Karlijn Verkerk (20366560)
Publié: (2025)

Supplementary Table S6 from Checkpoint Blockade Combinations in Tumor Mutational Burden/Load-High Tumors: Insights from the Atezolizumab + Bevacizumab and Nivolumab + Ipilimumab Cohorts in the Drug Rediscovery Protocol
par: Karlijn Verkerk (20366560)
Publié: (2025)

Supplementary Figures1 from The Ave–Rec Trial: Phase II Trial of PDL1/PD1 Blockade with Avelumab after Chemoradiotherapy for Locally Advanced Resectable T3B-4/N1-2 Rectal Cancer
par: Michael Michael (15021425)
Publié: (2025)

Supplementary Data from EDIL3 as an Angiogenic Target of Immune Exclusion Following Checkpoint Blockade
par: Saba Tabasum (17315027)
Publié: (2025)

Figure 1 from Combined Targeting of PD-1 and TIM-3 in Patients with Locally Advanced or Metastatic Non–Small Cell Lung Cancer: AMBER Part 2B
par: Diwakar Davar (15023480)
Publié: (2025)

Figure 2 from Combined Targeting of PD-1 and TIM-3 in Patients with Locally Advanced or Metastatic Non–Small Cell Lung Cancer: AMBER Part 2B
par: Diwakar Davar (15023480)
Publié: (2025)

Figure 3 from Combined Targeting of PD-1 and TIM-3 in Patients with Locally Advanced or Metastatic Non–Small Cell Lung Cancer: AMBER Part 2B
par: Diwakar Davar (15023480)
Publié: (2025)

Table 1 from Combined Targeting of PD-1 and TIM-3 in Patients with Locally Advanced or Metastatic Non–Small Cell Lung Cancer: AMBER Part 2B
par: Diwakar Davar (15023480)
Publié: (2025)

Table 2 from Combined Targeting of PD-1 and TIM-3 in Patients with Locally Advanced or Metastatic Non–Small Cell Lung Cancer: AMBER Part 2B
par: Diwakar Davar (15023480)
Publié: (2025)

Table 3 from Combined Targeting of PD-1 and TIM-3 in Patients with Locally Advanced or Metastatic Non–Small Cell Lung Cancer: AMBER Part 2B
par: Diwakar Davar (15023480)
Publié: (2025)

Supplementary Figure S1 from Comprehensive Genome Profiling in Patients With Metastatic Non–Small Cell Lung Cancer: The Precision Medicine Phase II Randomized SAFIR02-Lung/IFCT 1301 Trial
par: Fabrice Barlesi (15045504)
Publié: (2025)

Supplementary Figure S2 from Comprehensive Genome Profiling in Patients With Metastatic Non–Small Cell Lung Cancer: The Precision Medicine Phase II Randomized SAFIR02-Lung/IFCT 1301 Trial
par: Fabrice Barlesi (15045504)
Publié: (2025)

Supplementary Figure S3 from Comprehensive Genome Profiling in Patients With Metastatic Non–Small Cell Lung Cancer: The Precision Medicine Phase II Randomized SAFIR02-Lung/IFCT 1301 Trial
par: Fabrice Barlesi (15045504)
Publié: (2025)

Supplementary Figure S4 from Comprehensive Genome Profiling in Patients With Metastatic Non–Small Cell Lung Cancer: The Precision Medicine Phase II Randomized SAFIR02-Lung/IFCT 1301 Trial
par: Fabrice Barlesi (15045504)
Publié: (2025)

Supplementary Figure S5 from Comprehensive Genome Profiling in Patients With Metastatic Non–Small Cell Lung Cancer: The Precision Medicine Phase II Randomized SAFIR02-Lung/IFCT 1301 Trial
par: Fabrice Barlesi (15045504)
Publié: (2025)

Figure 1 from Combined Targeting of PD-1 and TIM-3 in Patients with Locally Advanced or Metastatic Melanoma: AMBER Cohorts 1c, 1e, and 2A
par: Diwakar Davar (15023480)
Publié: (2025)

Figure 2 from Combined Targeting of PD-1 and TIM-3 in Patients with Locally Advanced or Metastatic Melanoma: AMBER Cohorts 1c, 1e, and 2A
par: Diwakar Davar (15023480)
Publié: (2025)

Figure 3 from Combined Targeting of PD-1 and TIM-3 in Patients with Locally Advanced or Metastatic Melanoma: AMBER Cohorts 1c, 1e, and 2A
par: Diwakar Davar (15023480)
Publié: (2025)

Table 1 from Combined Targeting of PD-1 and TIM-3 in Patients with Locally Advanced or Metastatic Melanoma: AMBER Cohorts 1c, 1e, and 2A
par: Diwakar Davar (15023480)
Publié: (2025)

Table 2 from Combined Targeting of PD-1 and TIM-3 in Patients with Locally Advanced or Metastatic Melanoma: AMBER Cohorts 1c, 1e, and 2A
par: Diwakar Davar (15023480)
Publié: (2025)

Table 3 from Combined Targeting of PD-1 and TIM-3 in Patients with Locally Advanced or Metastatic Melanoma: AMBER Cohorts 1c, 1e, and 2A
par: Diwakar Davar (15023480)
Publié: (2025)

Figure S1 from A Phase II Study of Durvalumab for Bacillus Calmette-Guerin (BCG) Unresponsive Urothelial Carcinoma <i>In Situ</i> of the Bladder
par: Roger Li (17078665)
Publié: (2025)

Supplementary Tables 1 from A Phase II Trial of Guadecitabine plus Atezolizumab in Metastatic Urothelial Carcinoma Progressing after Initial Immune Checkpoint Inhibitor Therapy
par: H. Josh Jang (15206898)
Publié: (2025)

Figure 1 from First-in-Human Phase I/II Study of INCAGN01876, a Glucocorticoid-Induced Tumor Necrosis Factor Receptor Agonist, in Patients with Advanced or Metastatic Solid Tumors
par: Omid Hamid (15023912)
Publié: (2025)

Figure 2 from First-in-Human Phase I/II Study of INCAGN01876, a Glucocorticoid-Induced Tumor Necrosis Factor Receptor Agonist, in Patients with Advanced or Metastatic Solid Tumors
par: Omid Hamid (15023912)
Publié: (2025)

Figure 3 from First-in-Human Phase I/II Study of INCAGN01876, a Glucocorticoid-Induced Tumor Necrosis Factor Receptor Agonist, in Patients with Advanced or Metastatic Solid Tumors
par: Omid Hamid (15023912)
Publié: (2025)

Table 1 from First-in-Human Phase I/II Study of INCAGN01876, a Glucocorticoid-Induced Tumor Necrosis Factor Receptor Agonist, in Patients with Advanced or Metastatic Solid Tumors
par: Omid Hamid (15023912)
Publié: (2025)

Table 2 from First-in-Human Phase I/II Study of INCAGN01876, a Glucocorticoid-Induced Tumor Necrosis Factor Receptor Agonist, in Patients with Advanced or Metastatic Solid Tumors
par: Omid Hamid (15023912)
Publié: (2025)

Figure 1 from Efficacy and Safety of Nivolumab Monotherapy in Patients with High PD-1–Positive CD8/Treg Ratio in Advanced NSCLC and Gastric Cancer: A Phase II, Multicenter Study
par: Kohei Shitara (15043443)
Publié: (2025)

Figure 2 from Efficacy and Safety of Nivolumab Monotherapy in Patients with High PD-1–Positive CD8/Treg Ratio in Advanced NSCLC and Gastric Cancer: A Phase II, Multicenter Study
par: Kohei Shitara (15043443)
Publié: (2025)

Figure 3 from Efficacy and Safety of Nivolumab Monotherapy in Patients with High PD-1–Positive CD8/Treg Ratio in Advanced NSCLC and Gastric Cancer: A Phase II, Multicenter Study
par: Kohei Shitara (15043443)
Publié: (2025)

Table 1 from Efficacy and Safety of Nivolumab Monotherapy in Patients with High PD-1–Positive CD8/Treg Ratio in Advanced NSCLC and Gastric Cancer: A Phase II, Multicenter Study
par: Kohei Shitara (15043443)
Publié: (2025)

Table 2 from Efficacy and Safety of Nivolumab Monotherapy in Patients with High PD-1–Positive CD8/Treg Ratio in Advanced NSCLC and Gastric Cancer: A Phase II, Multicenter Study
par: Kohei Shitara (15043443)
Publié: (2025)